Attempts have been made to pharmacologically reduce TAMs in glioma, for example with CSF-1R inhibitors that decreased M2-like TAMs and increased survival in mouse transgenic and human xenograft glioblastoma models [48]. This evidence concerns the gene CSF1R and central nervous system cancer.